|
Adeona Pharmaceuticals, Inc. |
|
|
3930 Varsity Drive
Ann Arbor, MI 48108 USA
phone:(734) 332-7800
fax:(734) 332-7878
|
|
| Symbol |
AEN |
| Exchange |
AMEX |
| Founded |
2001 |
| Employees |
14 |
|
|
| www.adeonapharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Developing innovative medicines for the treatment of serious central nervous system diseases - Alzheimer's disease, multiple sclerosis, fibromyalgia, rheumatoid arthritis and age-related macular degeneration. |
|
| Management |
| - James S. Kuo, MD, MBA, CEO, President and Chairman;
- David A. Newsome, MD, Sr. Vice President of Research & Development;
- Julie A. Caudill, BBA, Vice President of Finance and Corporate Controller;
- Lara Guzman, BS, Vice President of Administration |
| |
|
|
|
|
|
|
|
| Keywords |
| alzheimer's disease, zinc, multiple sclerosis, estrogen, fibromyalgia, age-related macular degeneration, rheumatoid arthritis |
|
|
|
| Description |
|
Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is developing the following product candidates: a prescription medical food for Alzheimer's disease, and drugs for multiple sclerosis, fibromyalgia, rheumatoid arthritis and age-related macular degeneration. |
|
| Products / Services |
1-Alzheimer's disease - Zinthionein - an orally active, zinc-based compound for the dietary management of Alzheimer's disease and mild cognitive impairment (Status: pivotal clinical study)
2-Multiple sclerosis - TRIMESTA (oral, once daily, estriol)-an immunomodulatory and anti-inflammatory agent for the relapsing-remitting multiple sclerosis market in North America (Status: Phase II clinical trial)
3-Fibromyalgia - Flupirtine - a novel, centrally-active, oral therapy for the treatment of fibromyalgia syndrome (FMS) (Status: partnered with Meda AB in 2010)
4-Age-related macular degeneration - Zinc-monocysteine - oral complex of zinc and amino acid cysteine for the treatment of age-related macular degeneration (Status: clinical trial complete; developing further strategy)
5-Rheumatoid arthritis - dnaJP1 - an oral, once-daily epitope specific immunotherapy for the treatment of rheumatoid arthritis (RA) patients (Status: clinical trial complete; developing further strategy)
|
|
|
| Strategy |
Primary strategy: Focused on central nervous system diseases;
license product candidates with clinical efficacy; establish large pharma collaborations
Secondary strategy: Advance core competency in measuring metabolic serum zinc and copper levels. To further this effort, purchased Adeona Clinical Laboratory, the wholly-owned CLIA-certified clinical testing facility provides a broad array of chemistry and microbiology diagnostic tests in the Greater Chicago area.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
